Mitocin (Mitomycin)

Mitomycin, the active ingredient in Mitocin, is an alkylating agent presented as a solution for intravesical administration for use in the bladder. It is employed in the treatment of non‑muscle invasive bladder cancer, typically after transurethral resection, to reduce recurrence.

GNH USA supplies Mitocin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Mitocin, an intravesical alkylating agent, is used in the management of bladder cancer.

Non‑muscle invasive bladder cancer: reduces tumor recurrence after transurethral resection. Superficial bladder carcinoma: provides local cytotoxic effect to eradicate residual disease. Carcinoma in situ of bladder: helps achieve complete remission.

Mitocin may cause a range of adverse reactions following intravesical administration.

Common Side Effects: - Dysuria or bladder irritation - Increased urinary frequency or urgency - Hematuria or blood in urine - Mild abdominal discomfort - Transient low-grade fever - Local infection at catheter site

Serious or Rare Side Effects: - Myelosuppression (e.g., neutropenia, thrombocytopenia) - Acute renal impairment - Pulmonary toxicity or fibrosis - Severe allergic reaction (anaphylaxis) - Systemic absorption leading to gastrointestinal toxicity

Before using Mitocin, several safety considerations should be observed.

Monitor blood counts: regular CBC to detect myelosuppression. Assess renal function: evaluate serum creatinine and eGFR. Avoid in active urinary infection: treat infection prior to instillation. Use aseptic catheter technique: minimize risk of bladder injury and infection. Do not combine with other nephrotoxic or myelotoxic agents without specialist advice. Store at below 25°C: keep in original container, protect from light and moisture.

Mitocin can interact with other medicines, requiring attention to avoid harmful effects.

Major Interactions (Avoid): - Concurrent use of other alkylating agents: may amplify bone‑marrow toxicity. - Nephrotoxic drugs (e.g., aminoglycosides, cisplatin): increase risk of renal damage. - High‑dose radiotherapy to the pelvis: potentiates bladder toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor for hematuria. - Immunosuppressants: watch for heightened infection risk. - Drugs affecting hepatic metabolism (e.g., CYP450 inducers): may alter systemic exposure.